Diego Dos Santos Ferreira

Diego Dos Santos Ferreira

Auto-generated profile, based on publicly available information

Diego Dos Santos Ferreira

Athinoula A. Martinos Center for Biomedical Imaging, Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
SASarah Alsamman
Sarah Alsamman
SCStephanie A. Christenson
Stephanie A. Christenson
AYAmy Yu
Amy Yu
NANadia M. E. Ayad
Nadia M. E. Ayad
MMMeghan S. Mooring
Meghan S. Mooring
JCJennifer Y. Chen
Jennifer Y. Chen
Acid ceramidase inhibition promotes YAP/TAZ degradation to inactivate fibroblasts, decrease matrix stiffness, and reduce fibrosis in mice.

5 July 2017 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
PWPhilip A. Waghorn
Philip A. Waghorn
CJChloe M. Jones
Chloe M. Jones
NRNicholas J. Rotile
Nicholas J. Rotile
SKSteffi K. Koerner
Steffi K. Koerner
DFDiego S. Ferreira
Diego S. Ferreira
PCPeter Caravan
Peter Caravan

7 March 2018 in Hepatology Communications
Verified
Journal Article
Open access
PDF file
AKAnnie J. Kruger
Annie J. Kruger
BFBryan C. Fuchs
Bryan C. Fuchs
RMRicard Masia
Ricard Masia
JHJacinta A. Holmes
Jacinta A. Holmes
SSShadi Salloum
Shadi Salloum
RCRaymond T. Chung
Raymond T. Chung
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease projected to become the leading cause of cirrhosis and liver transplantation in the next decade. Cenicriviroc (CVC), a dual chemokine receptor 2 and 5 antagonist, prevents macrophage trafficking and is under clinical investigation for the treatment of human NASH fibrosis. We assessed the efficacy and durability of short and prolonged CVC therapy in a diet‐induced mouse model of NASH, the choline deficient, L‐amino acid‐defined, high‐fat diet (CDAHFD) model. C57BL/6 mice received 4 or 14 weeks of standard chow or the CDAHFD. CVC (10 mg/kg/day and 30 mg/kg/day for 4 weeks and 20 mg/kg/day and 30 mg/kg/day for 14 weeks) was initiated simultaneously with the CDAHFD. At 4 and 14 weeks, livers were harvested for histology and flow cytometric analyses of intrahepatic immune cells. High‐dose CVC (30 mg/kg/day) therapy in CDAHFD mice for 4 or 14 weeks inhibited intrahepatic accumulation of Ly6Chigh bone marrow‐derived macrophages. Prolonged CVC therapy (14 weeks) yielded no significant differences in the total intrahepatic macrophage populations among treatment groups but increased the frequency of intrahepatic anti‐inflammatory macrophages in the high‐dose CVC group. Despite ongoing steatohepatitis, there was significantly less fibrosis in CDAHFD mice receiving high‐dose CVC for 14 weeks based on histologic and molecular markers, mirroring observations in human NASH CVC trials. CVC also directly inhibited the profibrotic gene signature of transforming growth factor‐β‐stimulated primary mouse hepatic stellate cells in vitro. Conclusion: CVC is a novel therapeutic agent that is associated with reduced fibrosis despite ongoing steatohepatitis. Its ability to alter intrahepatic macrophage populations and inhibit profibrogenic genes in hepatic stellate cells in NASH livers may contribute to its observed antifibrotic effect. (Hepatology Communications 2018;2:529‐545)

21 May 2018 in Hepatology Communications
Verified
Journal Article
Open access
PDF file
DEDerek Erstad
Derek Erstad
CFChristian T. Farrar
Christian T. Farrar
SGSarani Ghoshal
Sarani Ghoshal
RMRicard Masia
Ricard Masia
DFDiego S. Ferreira
Diego S. Ferreira
BFBryan C. Fuchs
Bryan C. Fuchs
We examined a novel farnesoid X receptor agonist, EDP‐305, for its antifibrotic effect in bile duct ligation (BDL) and choline‐deficient, L‐amino acid‐defined, high‐fat diet (CDAHFD) models of hepatic injury. We used molecular magnetic resonance imaging with the type 1 collagen‐binding probe EP‐3533 and the oxidized collagen‐specific probe gadolinium hydrazide to noninvasively measure treatment response. BDL rats (n = 8 for each group) were treated with either low or high doses of EDP‐305 starting on day 4 after BDL and were imaged on day 18. CDAHFD mice (n = 8 for each group) were treated starting at 6 weeks after the diet and were imaged at 12 weeks. Liver tissue was subjected to pathologic and morphometric scoring of fibrosis, hydroxyproline quantitation, and determination of fibrogenic messenger RNA expression. High‐dose EDP‐305 (30 mg/kg) reduced liver fibrosis in both the BDL and CDAHFD models as measured by collagen proportional area, hydroxyproline analysis, and fibrogenic gene expression (all P < 0.05). Magnetic resonance signal intensity with both EP‐3533 in the BDL model and gadolinium hydrazide in the CDAHFD model was reduced with EDP‐305 30 mg/kg treatment (P < 0.01). Histologically, EDP‐305 30 mg/kg halted fibrosis progression in the CDAHFD model. Conclusion: EDP‐305 reduced fibrosis progression in rat BDL and mouse CDAHFD models. Molecular imaging of collagen and oxidized collagen is sensitive to changes in fibrosis and could be used to noninvasively measure treatment response in clinical trials. (Hepatology Communications 2018;2:821‐835)

1 October 2016 in Translational Oncology
Verified
Journal Article
Open access
VKVidhya Kumar
Vidhya Kumar
YBYves Boucher
Yves Boucher
HLHao Liu
Hao Liu
DFDiego Ferreira
Diego Ferreira
JHJacob Hooker
Jacob Hooker
AGAlexander R. Guimaraes
Alexander R. Guimaraes
Losartan, an angiotensin II receptor blocker, can reduce desmoplasia and enhance drug delivery and efficacy through improving interstitial transport and vascular perfusion in pancreatic ductal adenocarcinoma (PDAC) models in mice. The purpose of this study was to determine whether magnetic resonance imaging (MRI) of magnetic iron oxide nanoparticles (MNPs) and micro-positron emission tomography (PET) measurements could respectively detect improvements in tumor vascular parameters and drug uptake in orthotopic PDAC in mice treated with losartan. All experiments were approved by the local Institutional Animal Care and Use Committee. FVB mice with orthotopic PDAC were treated daily with an i.p. injection of losartan (70 mg/kg) or saline (control vehicle) for 5 days. In order to calculate the fractional blood volume, vessel size index, and vessel density index, MRI was performed at 4.7 T following the injection of 3 mg/kg iron ferumoxytol (i.v.). Dynamic PET images were also acquired for 60 minutes using an 18F-5FU tracer dose of 200 μCi and analyzed for time activity curves normalized to muscle. Statistical analyses compared both cohorts using an unpaired two-tailed t test. In comparison to the control treatment, the losartan administration significantly increased the fractional blood volume (mean±SEM) [12.1±1.7 (n=19) vs 6.7±1.1 (n=20); P<.02] and vessel size index (128.2±35.6 vs 57.5±18; P<.05). Losartan also induced a significant increase in the intratumoral uptake of 18F-5FU by 53% (P<.0001). MRI using FDA-approved MNPs provides a noninvasive, translatable means of assaying microvascular parameters induced by losartan in pancreatic cancer. PET measurements demonstrated that losartan significantly increased the uptake of 18F-5FU.

25 March 2019 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JWJessica Wahsner
Jessica Wahsner
PDPauline Désogère
Pauline Désogère
EAEric Abston
Eric Abston
KGKatherine A. Graham-O’rEgan
Katherine A. Graham-O’rEgan
JWJunfeng Wang
Junfeng Wang
PCPeter Caravan
Peter Caravan